Tel-Aviv, Israel-based RedHill Biopharma treated the last patient enrolled in its Bekinda's 24 mg phase III clinical trial.
Here's what you should know.
1. The company expects results in the second quarter of fiscal year 2017.
2. Researchers conducted a randomized, double-blind, placebo-controlled study of Bekinda in patients with acute gastroenteritis and gastritis.
3. If the FDA approves Bekinda, it would be the first 5-HT3 antiemtetic drug designed for acute gastroenteritis and gastritis available in the United States.
4. RedHill is conducting a phase II study for its 12 mg version. The lower dose can treat diarrhea-predominant irritable bowel syndrome. RedHill expects to report results in mid-2017.